{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:54:58Z","timestamp":1792788898656,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s00393-025-01667-3","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T09:32:18Z","timestamp":1750843938000},"page":"494-505","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["S2e-Leitlinie zur Behandlung der Polymyalgia rheumatica: Update 2024","S2e guidelines on the treatment of polymyalgia rheumatica: update 2024"],"prefix":"10.1007","volume":"84","author":[{"given":"F.","family":"Buttgereit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"DGRh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Boyadzhieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Reisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"\u00d6GR","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Brabant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"DGG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Daikeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"SGR","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Duftner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Erstling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Fachverband Rheumatologische Fachassistenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Garske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Deutsche Rheuma-Liga Bundesverband e.\u202fV.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Hellmich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Kyburz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rei\u00dfhauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"DGPRM","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Reu\u00df-Borst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"DGIM","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Scheuermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Steffens-Korbanka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Dejaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,25]]},"reference":[{"issue":"7","key":"1667_CR1","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00393-016-0105-3","volume":"75","author":"C Dejaco","year":"2016","unstructured":"Dejaco\u00a0C, Matteson\u00a0EL, Buttgereit\u00a0F (2016) Diagnostics and treatment of polymyalgia rheumatica. Z\u00a0Rheumatol 75(7):687\u2013700","journal-title":"Z Rheumatol"},{"key":"1667_CR2","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1001\/jama.2016.5444","volume":"315(22","author":"F Buttgereit","year":"2016","unstructured":"Buttgereit\u00a0F, Dejaco\u00a0C, Matteson\u00a0EL, Dasgupta\u00a0B (2016) Polymyalgia Rheumatica and Giant Cell Arteritis: A\u00a0Systematic Review. JAMA 315(22:2442\u20132458","journal-title":"JAMA"},{"issue":"11","key":"1667_CR3","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s40266-019-00705-5","volume":"36","author":"D Camellino","year":"2019","unstructured":"Camellino\u00a0D, Giusti\u00a0A, Girasole\u00a0G, Bianchi\u00a0G, Dejaco\u00a0C (2019) Pathogenesis, Diagnosis and Management of Polymyalgia Rheumatica. Drugs Aging 36(11):1015\u20131026","journal-title":"Drugs Aging"},{"issue":"4","key":"1667_CR4","first-page":"506","volume":"56","author":"C Dejaco","year":"2017","unstructured":"Dejaco\u00a0C, Duftner\u00a0C, Buttgereit\u00a0F, Matteson\u00a0EL, Dasgupta\u00a0B (2017) The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease. Rheumatol 56(4):506\u2013515","journal-title":"Rheumatol"},{"issue":"10103","key":"1667_CR5","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/S0140-6736(17)31825-1","volume":"390","author":"MA Gonzalez-Gay","year":"2017","unstructured":"Gonzalez-Gay\u00a0MA, Matteson\u00a0EL, Castaneda\u00a0S (2017) Polymyalgia rheumatica. Lancet 390(10103):1700\u20131712","journal-title":"Lancet"},{"issue":"5","key":"1667_CR6","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1093\/rheumatology\/key431","volume":"58","author":"C Manzo","year":"2019","unstructured":"Manzo\u00a0C, Milchert\u00a0M, Natale\u00a0M, Brzosko\u00a0M (2019) Polymyalgia rheumatica with normal values of both erythrocyte sedimentation rate and C\u2011reactive protein concentration at the time of diagnosis. Rheumatol 58(5):921\u2013923","journal-title":"Rheumatol"},{"issue":"39","key":"1667_CR7","doi-asserted-by":"publisher","first-page":"e35385","DOI":"10.1097\/MD.0000000000035385","volume":"102","author":"M Kara","year":"2023","unstructured":"Kara\u00a0M, Alp\u00a0G, Koc\u00a0AM (2023) Diagnostic difficulties in polymyalgia rheumatica cases with normal erythrocyte sedimentation rate and C\u2011reactive protein values. Med 102(39):e35385","journal-title":"Med"},{"issue":"1","key":"1667_CR8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.rdc.2015.08.009","volume":"42","author":"EL Matteson","year":"2016","unstructured":"Matteson\u00a0EL, Buttgereit\u00a0F, Dejaco\u00a0C, Dasgupta\u00a0B (2016) Glucocorticoids for Management of Polymyalgia Rheumatica and Giant Cell Arteritis. Rheum Dis Clin North Am 42(1):75\u201390 (viii)","journal-title":"Rheum Dis Clin North Am"},{"key":"1667_CR9","doi-asserted-by":"publisher","unstructured":"Fruth\u00a0M, K\u00fcnitz\u00a0L, Martin-Seidel\u00a0P, Tsiami\u00a0S, Baraliakos\u00a0X (2024) MRI of shoulder girdle in polymyalgia rheumatica: inflammatory findings and their diagnostic value. RMD Open 10(2):e004169. https:\/\/doi.org\/10.1136\/rmdopen-2024-004169","DOI":"10.1136\/rmdopen-2024-004169"},{"issue":"8","key":"1667_CR10","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1093\/rheumatology\/keac713","volume":"62","author":"AO Donskov","year":"2023","unstructured":"Donskov\u00a0AO, Mackie\u00a0SL, Hauge\u00a0EM, Toro-Gutierrez\u00a0CE, Hansen\u00a0IT, Hemmig\u00a0AK et\u00a0al (2023) An international survey of current management practices for polymyalgia rheumatica by general practitioners and rheumatologists. Rheumatol 62(8):2797\u20132805","journal-title":"Rheumatol"},{"key":"1667_CR11","doi-asserted-by":"publisher","unstructured":"Keller\u00a0KK, Mukhtyar\u00a0CB, Nielsen\u00a0AW, Hemmig\u00a0AK, Mackie\u00a0SL, Sattui\u00a0SE et\u00a0al (2024) Recommendations for early referral of individuals with suspected polymyalgia rheumatica:\nan initiative from the international giant cell arteritis and polymyalgia rheumatica study group. Ann Rheum Dis 83(11):1436\u20131442. https:\/\/doi.org\/10.1136\/ard-2023-225134","DOI":"10.1136\/ard-2023-225134"},{"issue":"10","key":"1667_CR12","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1136\/annrheumdis-2015-207492","volume":"74","author":"C Dejaco","year":"2015","unstructured":"Dejaco\u00a0C, Singh\u00a0YP, Perel\u00a0P, Hutchings\u00a0A, Camellino\u00a0D, Mackie\u00a0S et\u00a0al (2015) 2015 recommendations for the management of polymyalgia rheumatica: a\u00a0European League Against Rheumatism\/American College of Rheumatology collaborative initiative. Ann Rheum Dis 74(10):1799\u20131807","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1667_CR13","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s00393-018-0476-8","volume":"77","author":"F Buttgereit","year":"2018","unstructured":"Buttgereit\u00a0F, Brabant\u00a0T, Dinges\u00a0H, et\u00a0al (2018) S3 guidelines on treatment of polymyalgia rheumatica : Evidence-based guidelines of the German Society of Rheumatology (DGRh), the Austrian Society of Rheumatology and Rehabilitation (OGR) and the Swiss Society of Rheumatology (SGT) and participating medical scientific specialist societies and other organizations. Z\u00a0Rheumatol 77(5):429\u2013441","journal-title":"Z Rheumatol"},{"issue":"10","key":"1667_CR14","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1136\/annrheumdis-2015-207578","volume":"74","author":"C Dejaco","year":"2015","unstructured":"Dejaco\u00a0C, Singh\u00a0YP, Perel\u00a0P, Hutchings\u00a0A, Camellino\u00a0D, Mackie\u00a0S et\u00a0al (2015) Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: a\u00a0systematic literature review informing the 2015 European League Against Rheumatism\/American College of Rheumatology recommendations for the management of polymyalgia rheumatica. Ann Rheum Dis 74(10):1808\u20131817","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"1667_CR15","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1136\/ard-2024-225650","volume":"83","author":"S Cowley","year":"2024","unstructured":"Cowley\u00a0S, Harkins\u00a0P, Kirby\u00a0C, Conway\u00a0R, Kane\u00a0DJ (2024) Should all patients with polymyalgia rheumatica have a\u00a0vascular ultrasound assessment? Ann Rheum Dis 83(8):961\u2013964","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1667_CR16","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/ard-2022-223429","volume":"83","author":"C Dejaco","year":"2024","unstructured":"Dejaco\u00a0C, Kerschbaumer\u00a0A, Aletaha\u00a0D, Bond\u00a0M, Hysa\u00a0E, Camellino\u00a0D et\u00a0al (2024) Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica. Ann Rheum Dis 83(1):48\u201357","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1667_CR17","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.1097\/RHU.0000000000001969","volume":"30","author":"JP Vinicki","year":"2024","unstructured":"Vinicki\u00a0JP, Gut\u00a0O, Maliandi\u00a0MDR, Velasco Zamora\u00a0JL, Linarez\u00a0M, Cusa\u00a0MA et\u00a0al (2024) Risk Factors for Relapse and\/or Prolonged Glucocorticoid Therapy in Polymyalgia Rheumatica: Multicenter Study in 185 Patients. J\u00a0Clin Rheumatol 30(1):e34\u2013e38","journal-title":"J Clin Rheumatol"},{"issue":"4","key":"1667_CR18","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/s41584-020-0370-z","volume":"16","author":"F Buttgereit","year":"2020","unstructured":"Buttgereit\u00a0F (2020) Views on glucocorticoid therapy in rheumatology: the age of convergence. Nat Rev Rheumatol 16(4):239\u2013246","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"1667_CR19","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1136\/annrheumdis-2021-221126","volume":"81","author":"M Bonelli","year":"2022","unstructured":"Bonelli\u00a0M, Radner\u00a0H, Kerschbaumer\u00a0A, Mrak\u00a0D, Durechova\u00a0M, Stieger\u00a0J et\u00a0al (2022) Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a\u00a0phase\u00a02\/3 randomised controlled trial. Ann Rheum Dis 81(6):838\u2013844","journal-title":"Ann Rheum Dis"},{"key":"1667_CR20","first-page":"2196","volume":"74","author":"V Devauchelle","year":"2022","unstructured":"Devauchelle\u00a0V, Alegria\u00a0GC, Dernis\u00a0E, Richez\u00a0C, Truchetet\u00a0M, Wendling\u00a0D et\u00a0al (2022) Effect of Tocilizumab on Disease Activity in Patients with Active Polymyalgia Rheumatica on Glucocorticoid Therapy: a\u00a0Randomized Clinical Trial. Arthritis Rheumatol 74:2196\u20132198","journal-title":"Arthritis Rheumatol"},{"issue":"14","key":"1667_CR21","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1056\/NEJMoa2303452","volume":"389","author":"RF Spiera","year":"2023","unstructured":"Spiera\u00a0RF, Unizony\u00a0S, Warrington\u00a0KJ, Sloane\u00a0J, Giannelou\u00a0A, Nivens\u00a0MC et\u00a0al (2023) Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper. N\u00a0Engl J Med 389(14):1263\u20131272","journal-title":"N Engl J Med"},{"issue":"11","key":"1667_CR22","doi-asserted-by":"publisher","first-page":"e758","DOI":"10.1016\/S2665-9913(21)00245-9","volume":"3","author":"DE Marsman","year":"2021","unstructured":"Marsman\u00a0DE, den Broeder\u00a0N, van den NHoogen\u00a0FHJ, den Broeder\u00a0AA, van der Maas\u00a0A (2021) Efficacy of rituximab in patients with polymyalgia rheumatica: a\u00a0double-blind, randomised, placebo-controlled, proof-of-concept trial. Lancet Rheumatol 3(11):e758\u2013e766","journal-title":"Lancet Rheumatol"},{"issue":"4","key":"1667_CR23","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.1016\/S2665-9913(23)00032-2","volume":"5","author":"TE Bolhuis","year":"2023","unstructured":"Bolhuis\u00a0TE, Marsman\u00a0DE, den Broeder\u00a0AA, den Broeder\u00a0N, van der Maas\u00a0A (2023) 1\u2011year results of treatment with rituximab in polymyalgia rheumatica: an extension study of a\u00a0randomised double-blind placebo-controlled trial. Lancet Rheumatol 5(4):e208\u2013e214","journal-title":"Lancet Rheumatol"},{"issue":"6","key":"1667_CR24","doi-asserted-by":"publisher","first-page":"e1004249","DOI":"10.1371\/journal.pmed.1004249","volume":"20","author":"X Ma","year":"2023","unstructured":"Ma\u00a0X, Yang\u00a0F, Wu\u00a0J, Xu\u00a0B, Jiang\u00a0M, Sun\u00a0Y et\u00a0al (2023) Efficacy and Safety of Tofacitinib in Patients with Polymyalgia Rheumatica (EAST PMR): An open-label randomized controlled trial. PLoS Med 20(6):e1004249","journal-title":"PLoS Med"},{"key":"1667_CR25","doi-asserted-by":"publisher","unstructured":"Saraux\u00a0A, Carvajal Alegria\u00a0G, Dernis\u00a0E, Roux\u00a0C, Richez\u00a0C, Tison\u00a0A et\u00a0al (2025) Baricitinib in early polymyalgia rheumatica (BACHELOR): a\u00a0randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Rheumatol 7(4):e233\u2013e242. https:\/\/doi.org\/10.1016\/S2665-9913(24)00270-4","DOI":"10.1016\/S2665-9913(24)00270-4"},{"issue":"2","key":"1667_CR26","doi-asserted-by":"publisher","first-page":"rkae033","DOI":"10.1093\/rap\/rkae033","volume":"8","author":"JP Vinicki","year":"2024","unstructured":"Vinicki\u00a0JP, Cusa\u00a0A, Domingo\u00a0D, Velasco Zamora\u00a0JL, Magri\u00a0S, Brigante\u00a0A et\u00a0al (2024) Effectiveness of methotrexate and leflunomide as corticoid-sparing drugs in patients with polymyalgia rheumatica. Rheumatol Adv Pract 8(2):rkae33","journal-title":"Rheumatol Adv Pract"},{"issue":"12","key":"1667_CR27","doi-asserted-by":"publisher","first-page":"e728","DOI":"10.1016\/S2665-9913(23)00246-1","volume":"5","author":"A Saraux","year":"2023","unstructured":"Saraux\u00a0A, Le Henaff\u00a0C, Dernis\u00a0E, Carvajal-Alegria\u00a0G, Tison\u00a0A, Quere\u00a0B et\u00a0al (2023) Abatacept in early polymyalgia rheumatica (ALORS): a\u00a0proof-of-concept, randomised, placebo-controlled, parallel-group trial. Lancet Rheumatol 5(12):e728\u2013e735","journal-title":"Lancet Rheumatol"},{"issue":"4","key":"1667_CR28","doi-asserted-by":"publisher","first-page":"105730","DOI":"10.1016\/j.jbspin.2024.105730","volume":"91","author":"D Wendling","year":"2024","unstructured":"Wendling\u00a0D, Al Tabaa\u00a0O, Chevet\u00a0B, Fakih\u00a0O, Ghossan\u00a0R, Hecquet\u00a0S et\u00a0al (2024) Recommendations of the French Society of Rheumatology for the management in current practice of patients with polymyalgia rheumatica. Joint Bone Spine 91(4):105730","journal-title":"Joint Bone Spine"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-025-01667-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-025-01667-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-025-01667-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T22:37:52Z","timestamp":1757198272000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-025-01667-3"}},"subtitle":["Evidenzbasierte Leitlinie der Deutschen Gesellschaft f\u00fcr Rheumatologie und Klinische Immunologie (DGRh), der \u00d6sterreichischen Gesellschaft f\u00fcr Rheumatologie und Rehabilitation (\u00d6GR) und der Schweizerischen Gesellschaft f\u00fcr Rheumatologie (SGR) und der beteiligten medizinisch-wissenschaftlichen Fachgesellschaften und weiterer Organisationen","Evidence-based guidelines of the German Society for Rheumatology and Clinical Immunology (DGRh), the Austrian Society for Rheumatology and Rehabilitation (\u00d6GR) and the Swiss Society for Rheumatology (SGR) and the participating medical scientific specialist societies and other organizations"],"short-title":[],"issued":{"date-parts":[[2025,6,25]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1667"],"URL":"https:\/\/doi.org\/10.1007\/s00393-025-01667-3","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,25]]},"assertion":[{"value":"7 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F.\u00a0Buttgereit: Berater- und\/oder Referentenhonorare durch die Firmen Horizon Therapeutics, Mundipharma, Novartis und Sanofi. M.\u00a0Schneider: Honorare f\u00fcr Beratung, Vortr\u00e4ge und Drittmittel: AbbVie, AstraZeneca, BMS, Boehringer Ingelheim, Chugai, GSK, Janssen-Cilag, Lilly, Novartis, Pfizer, Roche, und UCB. T.\u00a0Brabant: Berater- und\/oder Referentenhonorare durch die Firmen Lilly, Novartis und Amgen. T.\u00a0Daikeler: Berater- und\/oder Referentenhonorare durch die Firmen Novartis und Sanofi. C.\u00a0Duftner: Berater- und\/oder Referentenhonorare durch die Firmen AbbVie, AOP Orphan, AstraZeneca, Bristol-Myers Squibb, Eli-Lilly, Janssen, Galapagos, Merck-Sharp-Dohme, Novartis, Pfizer, Roche, Sandoz, UCB, Vifor, Forschungsunterst\u00fctzung durch Eli-Lilly, Pfizer, UCB. U.\u00a0Erstling: Berater und\/oder Referentenhonorare durch die Firmen AbbVie, Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Fresenius Kabi, Galapagos, GILEAD, Gsk, Janssen-Cilag, Lilly, medac, Sanofi-Aventis, Sobi, Stadapharm, UCB. B.\u00a0Hellmich: Honorare f\u00fcr Beratung und Vortr\u00e4ge: AbbVie, Alexion, Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Chugai, GSK, Hansa, InflaRx, Janssen-Cilag, MSD, Novartis, Pfizer, Recordati, Roche, Vifor. D.\u00a0Kyburz: Berater- und\/oder Referentenhonorare durch die Firmen AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, Roche, Sanofi und UCB. P.\u00a0Steffens-Korbanka: Berater und\/oder Referentenhonorare durch die Firmen: AbbVie, Amgen, AstraZeneca, Biogen, BMS, Boehringer Ingelheim, Chugai, Fresenius, Galapagos, GSK, Janssen-Cilag, Lilly, Novartis, Pfizer, Sanofi, UCB, Sobi, Viatris. C.\u00a0Dejaco: Berater- und\/oder Referentenhonorare durch die Firmen UCB, AbbVie, Roche, Pfizer, Novartis, Sanofi, Galapagos, Janssen und Lilly. Forschungsunterst\u00fctzung (unrestricted grant) durch AbbVie. Z.\u00a0Boyadzhieva, M.\u00a0Reisch, U.\u00a0Garske, A.\u00a0Rei\u00dfhauer, M.\u00a0Reu\u00df-Borst und K.\u00a0Scheuermann geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}